Activity Overview
The management of esophagogastric adenocarcinoma has evolved substantially with the introduction of effective targeted and immunologic therapies. However, these therapies are appropriate mainly for patients with specific biomarkers, necessitating careful coordination among the multidisciplinary team to ensure proper tissue stewardship and testing, which, in turn, allows for appropriate treatment selection and sequencing as well as the management and mitigation of adverse events.
In this webcast, experts in the management of esophagogastric adenocarcinoma discuss recent changes in the standard of care for HER2-positive (HER2+) disease, with a focus on selecting among multiple available options. These points are discussed in the context of patient case scenarios that highlight challenges in the management of HER2+ esophagogastric cancers.
This educational activity is an archive of the live virtual symposium held on May 15, 2026.
Target Audience
This educational program is primarily directed toward medical oncologists, molecular pathologists, radiologists, gastroenterologists, advanced practice providers, and nurses involved in the management of patients with advanced or metastatic GEA.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate the latest evidence on HER2-directed therapies into individualized treatment plans for patients with advanced gastroesophageal adenocarcinomas (GEA)
- Evaluate emerging clinical trial data assessing novel HER2-targeted treatment strategies for GEA
Pashtoon Kasi, MD, MS
Associate Clinical Professor
Department of Medical Oncology and Therapeutics Research
Medical Director, GI Medical Oncology
Department of Medical Oncology
Endowed Rad Family Chair in Gastrointestinal Oncology
City of Hope
Irvine, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Agenus, Bexion Pharmaceuticals, Boston Scientific, Elicio Therapeutics, Exact Sciences, Illumina, NeoGenomics, Regeneron Pharmaceuticals, RenovoRx, Sirtex Medical; Grant/Research Funding: Agenus, CytoDyn, Haystack, Merck, Novartis; Scientific Advisory Board (SAB) Member: Elicio Therapeutics
Elizabeth Conner, MD
Assistant Clinical Professor
Department of Medical Oncology and Therapeutics Research
City of Hope
Irvine, CA
Disclosures: Elizabeth Conner, MD, has no relevant financial relationships with ineligible companies.
Simona De Michele, MD
Assistant Clinical Professor
Department of Pathology
City of Hope
Irvine, CA
Disclosures: Simona De Michele, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here